Barclays PLC I Mab Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in I Mab stock. As of the latest transaction made, Barclays PLC holds 30,370 shares of IMAB stock, worth $29,458. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,370

Previous 30,370 -0.0%

Holding current value

$29,458

Previous $38,000 31.58%

% of portfolio

0.0%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.58 - $1.9 $12,927 - $15,545	-8,182 Reduced 21.22%	30,370 $51,000
Q1 2024 May 15, 2024	SELL	$1.54 - $2.37 $207,148 - $318,793	-134,512 Reduced 77.72%	38,552 $72,000
Q4 2023 Feb 15, 2024	BUY	$1.21 - $1.9 $73,322 - $115,134	60,597 Added 53.88%	173,064 $329,000
Q2 2023 Aug 03, 2023	SELL	$2.95 - $3.85 $937,920 - $1.22 Million	-317,939 Reduced 73.87%	112,467 $336,000
Q1 2023 May 04, 2023	BUY	$3.08 - $7.39 $311,406 - $747,173	101,106 Added 30.7%	430,406 $1.49 Million
Q4 2022 Feb 13, 2023	BUY	$3.22 - $4.86 $1.06 Million - $1.6 Million	329,300 New	329,300 $1.38 Million
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $1.99 Million - $4.44 Million	-240,881 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $3.02 Million - $11.3 Million	240,881 New	240,881 $3.91 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

16.5M

Call Options Held

Put Options Held

14.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $80.6M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account